Compare WNEB & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WNEB | ACHV |
|---|---|---|
| Founded | 1853 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.8M | 726.5M |
| IPO Year | 2001 | 2018 |
| Metric | WNEB | ACHV |
|---|---|---|
| Price | $13.94 | $8.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $13.67 | ★ $14.67 |
| AVG Volume (30 Days) | 42.0K | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 33.93 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $44,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.25 | N/A |
| P/E Ratio | $32.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.78 | $2.62 |
| 52 Week High | $15.01 | $8.64 |
| Indicator | WNEB | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 60.88 |
| Support Level | $13.42 | $4.03 |
| Resistance Level | $14.13 | $8.63 |
| Average True Range (ATR) | 0.37 | 0.37 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 66.67 | 75.46 |
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.